Abstract
The keynote address of the 2018 Pulmonary Hypertension Association (PHA) Scientific Sessions given by Dr Roham Zamanian, “From Clinical Classification to Precision-Phenotyping: Envisioning Precision Medicine in Pulmonary Hypertension,” was the perfect prelude to the final session of the symposium. In this session the speakers tackled the timely question: “Omics and Wearables in Pulmonary Hypertension: Are We There Yet?” Dr Michael Snyder of Stanford University described how longitudinal, integrative personal omics profiling that incorporate whole genome sequencing, multidimensional omics measurements, and data from wearables can be applied to: 1) determine what it means to be healthy; 2) potentially predict transitions from health to disease prior to symptom development; and 3) better monitor and treat chronic disease. Dr Anna Hemnes of Vanderbilt University shared promising preliminary data from the ongoing multicenter, collaborative PVDOMICS initiative (Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics), funded by the National Heart, Lung and Blood Institute (NHLBI) and PHA. Finally, Dr Raymond Benza of the Allegheny Health Network shared intriguing pilot data on the safety and utility of an implantable hemodynamic monitoring device, the CardioMEMS™ HF system, in patients with advanced pulmonary arterial hypertension (PAH).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
